Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

NCT01471574 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

549

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Genotype 1

Interventions

DRUG: Daclatasvir
DRUG: Ribavirin
DRUG: PEG-Interferon alfa 2a

Sponsor

Bristol-Myers Squibb